Cerebral Amyloid-β Deposition, Axial Features, and Cognitive Alterations in Patients with Parkinson’s Disease Treated with Bilateral STN-DBS: A Long-Term Cohort Study
2024

Cerebral Amyloid-β Deposition in Parkinson's Patients After Deep Brain Stimulation

Sample size: 19 publication Evidence: moderate

Author Information

Author(s): Francesco Cavallieri, Alessandro Fraternali, Annachiara Arnone, Isabella Campanini, Alessandro Marti, Annalisa Gessani, Valentina Fioravanti, Maria Angela Molinari, Giulia Di Rauso, Francesca Antonelli, Vittorio Rispoli, Alberto Feletti, Riccardo Stanzani, Benedetta Damiano, Sara Scaltriti, Lorenzo Cavazzuti, Elisa Bardi, Maria Giulia Corni, Francesca Cavalleri, Giuseppe Biagini, Giacomo Pavesi, Mirco Lusuardi, Carla Budriesi, Andrea Merlo, Annibale Versari, Franco Valzania, Egon Kurča

Primary Institution: Azienda USL-IRCCS di Reggio Emilia

Hypothesis

What is the long-term effect of subthalamic nucleus deep brain stimulation (STN-DBS) on cerebral amyloid-β deposition in Parkinson's disease patients?

Conclusion

A significant percentage of Parkinson's disease patients may present brain amyloid-β deposition long-term after STN-DBS.

Supporting Evidence

  • 21% of patients showed amyloid-β deposition in the brain.
  • Patients with amyloid-β deposition had higher preoperative UPDRS-I scores.
  • The study included a five-year postoperative follow-up.

Takeaway

Some people with Parkinson's disease who had brain surgery might have a sticky substance in their brains called amyloid-β, which could affect their thinking and movement later on.

Methodology

The study included 19 Parkinson's disease patients treated with bilateral STN-DBS, evaluated for amyloid-β deposition using PET scans and assessed for axial and cognitive symptoms.

Potential Biases

Selection bias may exist as patients with cognitive impairment or severe axial symptoms are usually excluded from surgery.

Limitations

The small sample size limits the statistical power and generalizability of the results.

Participant Demographics

19 patients (11 male, mean age 63.52 years) with a history of Parkinson's disease and disabling motor complications.

Statistical Information

P-Value

0.037

Statistical Significance

p = 0.037

Digital Object Identifier (DOI)

10.3390/jpm14121150

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication